Y-mAbs Therapeutics Reports Q1 2025 Financial Results

Y-Mabs Therapeutics ( (YMAB) ) has released its Q1 earnings. Here is a breakdown of the information Y-Mabs Therapeutics presented to its investors.

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative radioimmunotherapy and antibody-based cancer treatments.

In its first quarter of 2025, Y-mAbs Therapeutics reported net product revenues of $20.9 million, marking an 8% year-over-year increase. The company also highlighted significant advancements in its clinical trials and strategic business realignment.

Key financial highlights include a 5% increase in total revenues compared to the previous year, driven by a substantial rise in Ex-U.S. DANYELZA revenues. However, U.S. DANYELZA revenues saw a decline due to market dynamics. The company also reported a net loss of $5.2 million, an improvement from the previous year’s $6.6 million loss, attributed to increased revenues and foreign currency gains.

Strategically, Y-mAbs has dosed its first patient in a Phase 1 clinical trial for its CD38-SADA pretargeted radioimmunotherapy platform and plans to share updates on its radiopharmaceutical business strategy later this month. The company has also realigned its operations into two business units, focusing on DANYELZA and Radiopharmaceuticals.

Looking ahead, Y-mAbs maintains its full-year 2025 revenue guidance between $75 million and $90 million, with expectations to continue supporting operations into 2027, driven by anticipated DANYELZA revenues and strategic investments in its innovative platforms.